Akums launches Ripasudil + Timolol combination for glaucoma treatment

The new combination therapy offers a dual mechanism of action for superior intraocular pressure control

Caplin Point receives EIR from FDA with Zero 483 observations

The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.

Alembic Pharmaceuticals gets USFDA tentative approval for OTC

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander

Gland Pharma receives approval for Latanoprost Opthalmic Solution, 0.005%

The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan

Lupin launches first generic of Pred Forte in US

Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte

Lupin and Scope sign agreement for commercialization of Optase in Mexico

The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions

ANVISA completes inspection at Caplin Steriles' facility at Gummidipoondi

Caplin Point announces completion of unannounced USFDA inspection

The inspection was concluded with zero observations

Lupin completes successful Phase 3 trials for Lucentis biosimilar

The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU

Industry hails Union Budget 2024-25

The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable